|
Market Cap (5-Jun) $61,568,592 (1,444th) |
Close (30-Jun) $0.076 |
Volume (30-Jun) 120,981 |
Shortsold (26-May) 11,577 (0.00%) (629th) |
|
52w High $0.425 |
52w Low $0.056 |
P/E - |
EPS -0.02 |
ATX released this announcement to the ASX on 23 July 2021, 13:39. The announcement is not marked as price sensitive, and is 16 page(s) in length and 493.5kb in size.
You can view all announcements from ATX and see how they appear on a price chart on the announcements page.
At the date of this announcement, ATX was 0.012% short sold according to ASIC data. It was ranked the 606th most shorted stock on the ASX. It remains ranked 629th as of the latest reported data (26 May 2026).
| Other Recent Announcements from ATX | |
|---|---|
| AMP945 International Nonproprietary Name Narmafotinib | 21 June 2023, 8:34 |
| Amplia AGM to be held Thursday 24 August 2023 | 19 June 2023, 17:34 |
| Key to Corporate Governance Disclosures | 31 May 2023, 8:14 |
| Notice of Annual General Meeting/Proxy Form | 23 July 2021, 13:39 |
| Results from Successful Phase 1 Clinical Trial of AMP945 | 21 July 2021, 8:21 |
| Financial Report YE 31 March 2021 - Audited | 29 June 2021, 15:43 |
| Amplia and Garvan Enter Into Collaboration Agreement | 28 June 2021, 8:32 |
You must be logged in to post a reply.
Amplia Therapeutics 